Dermira is a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients. Our current portfolio includes three late-stage product candidates, Cimzia (certolizumab pegol), for the treatment of moderate to severe plaque psoriasis, DRM04, for the treatment of hyperhidrosis, or excessive sweating and DRM01, a topical sebum inhibitor for acne.
Company Growth (employees)
Type
Public
HQ
Menlo Park, US
Founded
2011
Size (employees)
95 (est)+54%
Dermira was founded in 2011 and is headquartered in Menlo Park, US

Key People at Dermira

Thomas G. Wiggans

Thomas G. Wiggans

Co-Founder & CEO
Kin Chan

Kin Chan

Vice President of Engineering
Janice Drew

Janice Drew

Vice President & Project Management
Eugene A. Bauer

Eugene A. Bauer

Founder & Chief Medical Officer
Hans Hofland

Hans Hofland

Vice President ofResearch
Chris Griffith

Chris Griffith

Founder & Vice President, Corporate Development & Strategy

Dermira Office Locations

Dermira has office in Menlo Park
Menlo Park, US

Dermira Metrics

Dermira Summary

Market capitalization

$1.2 b

Closing share price

$35.5
Dermira's current market capitalization is $1.2 b.

Dermira Financials

Dermira's revenue is $7.3 m in FY, 2015
FY, 2014FY, 2015FY, 2016

Revenue

$7.3 m$22.6 m

Revenue growth, %

209.4%

Operating expense total

$39 m$86.9 m

EBIT

($31.7 m)($79.6 m)

Net Income

($31.9 m)($78.4 m)($89.1 m)

Operating cash flow

$33.2 m$51.9 m

Dermira Market Value History

We estimate that Dermira's current employees are approximately 31% female and 69% male.

Dermira Company Life

You may also be interested in